[{"orgOrder":0,"company":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Hematology","graph2":"Phase IV","graph3":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo \/ Merck & Co"},{"orgOrder":0,"company":"University of Queensland","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Queensland \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"University of Queensland \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Hematology","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Merck & Co"},{"orgOrder":0,"company":"Sunshine Coast Hospital and Health Service","sponsor":"The Prince Charles Hospital | Mater","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Sunshine Coast Hospital and Health Service","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Coast Hospital and Health Service \/ The Prince Charles Hospital | Mater","highestDevelopmentStatusID":"11","companyTruncated":"Sunshine Coast Hospital and Health Service \/ The Prince Charles Hospital | Mater"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Weill Medical College of Cornell University \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Weill Medical College of Cornell University \/ Merck & Co"}]

Find Clinical Drug Pipeline Developments & Deals for Ceftolozane Sulfate

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check USDMF database

Contact Us
PharmaScopic.com

Ceftolozane Sulfate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

4 API Suppliers, 1 KDMF, 1 NDC API, 3 Listed Suppliers

DEVELOPMENTS

22 Drugs in Development

22 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

6 FDF Dossiers, 1 FDA Orange Book, 3 Europe, 1 Canada, 1 South Africa

RELATED EXCIPIENT COMPANIES

1 Pfanstiehl, 2 Kirsch Pharma, 2 Actylis, 1 Pluviaendo

EXCIPIENTS BY APPLICATIONS

4 Parenteral, 1 API Stability Enhancers, 1 Thickeners and Stabilizers

DIGITAL CONTENT

18 News #PharmaBuzz

18 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 2 Regulatory FDF Prices, 6 Annual Reports

MARKET PLACE

10 APIs

10 APIs

PATENTS & EXCLUSIVITIES

28 US Patents, 1 US Exclusivities

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Beneficência Portuguesa de São Paulo

Country

World Drug Safety EU

Not Confirmed

02

Sunshine Coast Hospital and Health Service

Country

World Drug Safety EU

Not Confirmed

03

Hamad Medical Corporation

Country

World Drug Safety EU

Not Confirmed

04

Weill Medical College of Cornell University

Country

World Drug Safety EU

Not Confirmed

05

University of Queensland

Country

World Drug Safety EU

Not Confirmed

06

Merck & Co

U.S.A

World Drug Safety EU

Not Confirmed

07

Merck & Co

U.S.A

World Drug Safety EU

Not Confirmed

08

MD Anderson Cancer Center

Country

World Drug Safety EU

Not Confirmed

09

Merck & Co

U.S.A

World Drug Safety EU

Not Confirmed

10

Merck & Co

U.S.A

World Drug Safety EU

Not Confirmed

1
2
3